Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Open Forum
How pharma can bridge the 'Valley of Death'
Access to not for profit ideas can help pharma companies if they take a more collaborative approach, writes Dr Alessandra Muntoni, director research at the National Breast Cancer Foundation.
Pipeline Monitor
Gilead continues to build in HCV/HIV
More Gilead Hepatitis C and HIV combos have been approved; Teva has had a new asthma bilogical recommended while Roche has filed MS treatments.
Working Life
Wellness program boosts bottom line
Workplace wellness programs don't only affect employees but also impact the corporate bottom line a new survey shows.
Approvals Action
New forms dominate registrations
A new progesterone product and a new formulation of antipsychotic quetiapine were the highlights of latest round of new medicine registrations.
Special Report
Election has ignored real pharma issues
Next Saturday's election will be a mere speed bump for the deep-seated medicines access and innovation issues that divide pharma and government. Whatever the result, a new focus will be required.